Human genes that encode proteins often contain non-coding segments known as introns. Removing introns is crucial for the proper expression of genetic information. Understanding how our cells ...

A team of Chinese scientists has used targeted gene editing to develop rice that produces coenzyme Q10 (CoQ10), a vital ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Currently, people with high cholesterol face complicated treatment plans, usually taking a range of medications for the rest ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Operator: Thank you for standing by, and welcome to the Origin Agritech Fiscal Year 2024 Conference Call. Please note that, today ...